{"filing":{"accession_number":"0001193125-26-347315","cik":"0001637715","ticker":"OKUR","company_name":"OnKure Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-12","report_date":"2026-08-07","primary_document":"okur-20260807.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1637715/000119312526347315/okur-20260807.htm"},"events":[{"id":27385,"run_id":24951,"accession_number":"0001193125-26-347315","anchor_item_number":"5.02","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"This disclosure describes a Board-approved repricing of underwater stock options held by named executive officers and other employees, reducing exercise prices from a range of $13.99–$24.59 per Share to $4.14 per Share. The repricing affects approximately 1.7 million shares and includes retention requirements designed to incentivize continued service. This is a compensatory arrangement modification under Item 5.02(e), distinct from an executive departure or appointment, and materially affects the value of equity compensation for the CEO, CMO, and CFO.","company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","filing_date":"2026-08-12","form":"8-K","submitted_at":null,"items":[{"id":28898,"accession_number":"0001193125-26-347315","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This disclosure describes a Board-approved repricing of underwater stock options held by named executive officers and other employees, reducing exercise prices from a range of $13.99–$24.59 per Share to $4.14 per Share. The repricing affects approximately 1.7 million shares and includes retention requirements designed to incentivize continued service. This is a compensatory arrangement modification under Item 5.02(e), distinct from an executive departure or appointment, and materially affects the value of equity compensation for the CEO, CMO, and CFO.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-13T10:03:52.866865+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28898,"accession_number":"0001193125-26-347315","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This disclosure describes a Board-approved repricing of underwater stock options held by named executive officers and other employees, reducing exercise prices from a range of $13.99–$24.59 per Share to $4.14 per Share. The repricing affects approximately 1.7 million shares and includes retention requirements designed to incentivize continued service. This is a compensatory arrangement modification under Item 5.02(e), distinct from an executive departure or appointment, and materially affects the value of equity compensation for the CEO, CMO, and CFO.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-13T10:03:52.866865+00:00","company_name":"OnKure Therapeutics, Inc.","ticker":"OKUR","filing_date":"2026-08-12"}]}